Abstract
Active immunotherapy alone may be insufficient to treat advanced disease but may be a viable option in the adjuvant setting. Response evaluation criteria in solid tumors may not satisfy the criteria for judging effective immunotherapy. Immune-related response criteria will be needed to accurately assess objective responses to immunotherapeutics. Mucin 1, TGF-b and EGF vaccines may be useful in the locally advanced and metastatic setting. Melanoma-associated antigen-A3 vaccine is currently being investigated in patients with completely resected stage IB-IIIA non-small-cell lung cancer. Predictive gene signatures may help to select patients that will likely benefit from a certain immunotherapy.
Original language | English (US) |
---|---|
Title of host publication | Targeted Therapies for Non-Small-Cell Lung Cancer |
Publisher | Future Medicine Ltd. |
Pages | 89-101 |
Number of pages | 13 |
ISBN (Electronic) | 9781780840468 |
ISBN (Print) | 9781780841236 |
DOIs | |
State | Published - Oct 1 2012 |
ASJC Scopus subject areas
- General Medicine